Price T Rowe Associates Inc. MD cut its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 23.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,939,241 shares of the company's stock after selling 902,261 shares during the period. Price T Rowe Associates Inc. MD owned approximately 1.10% of Autolus Therapeutics worth $6,908,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in AUTL. Barclays PLC raised its stake in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after acquiring an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the fourth quarter worth $35,000. Arkadios Wealth Advisors acquired a new position in shares of Autolus Therapeutics during the fourth quarter worth $47,000. Daiwa Securities Group Inc. increased its holdings in Autolus Therapeutics by 55.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. Finally, Avanza Fonder AB bought a new position in Autolus Therapeutics in the fourth quarter valued at about $75,000. 72.83% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently commented on AUTL shares. Truist Financial cut their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Wells Fargo & Company decreased their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $9.32.
Check Out Our Latest Stock Report on AUTL
Autolus Therapeutics Stock Performance
Shares of NASDAQ AUTL traded up $0.05 during trading on Wednesday, hitting $1.23. 2,989,842 shares of the company traded hands, compared to its average volume of 1,431,267. The firm has a market capitalization of $325.97 million, a price-to-earnings ratio of -1.01 and a beta of 1.77. The business's fifty day moving average is $1.56 and its 200 day moving average is $2.31. Autolus Therapeutics plc has a fifty-two week low of $1.11 and a fifty-two week high of $5.00.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. On average, analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current year.
Autolus Therapeutics Profile
(
Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
